Molecule Holdings Past Earnings Performance
Past criteria checks 0/6
Molecule Holdings has been growing earnings at an average annual rate of 10.7%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 11.6% per year.
Key information
10.7%
Earnings growth rate
11.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 11.6% |
Return on equity | n/a |
Net Margin | -194.2% |
Last Earnings Update | 31 Jul 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Molecule Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jul 23 | 2 | -3 | 2 | 0 |
30 Apr 23 | 2 | -4 | 2 | 0 |
31 Jan 23 | 2 | -4 | 3 | 0 |
31 Oct 22 | 2 | -5 | 3 | 0 |
31 Jul 22 | 2 | -4 | 3 | 0 |
30 Apr 22 | 1 | -4 | 2 | 0 |
31 Jan 22 | 1 | -5 | 3 | 0 |
31 Oct 21 | 0 | -4 | 3 | 0 |
31 Jul 21 | 0 | -6 | 3 | 0 |
30 Apr 21 | 0 | -5 | 3 | 0 |
31 Jan 21 | 0 | -4 | 2 | 0 |
31 Oct 20 | 0 | -3 | 2 | 0 |
31 Jul 20 | 0 | -2 | 2 | 0 |
30 Apr 20 | 0 | -2 | 2 | 0 |
31 Jan 20 | 0 | -1 | 1 | 0 |
Quality Earnings: EVRR.F is currently unprofitable.
Growing Profit Margin: EVRR.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EVRR.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EVRR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVRR.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: EVRR.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.